v3.26.1

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2026	Jun. 30, 2025
Current assets:
Cash and cash equivalents	$ 19,440,655	$ 14,210,745
Accounts receivable, non-trade	1,605,340	11,948
Restricted cash		77,945
Prepaid expenses	611,913	740,193
Total current assets	21,657,908	15,040,831
Property and equipment, net		2,771
Intangible assets, net	4,307,743	4,804,791
Operating lease right-of-use assets		102,612
Goodwill	8,843,549	8,638,609
Total assets	34,809,200	28,589,614
Current liabilities:
Accounts payable	627,185	1,154,369
Accrued expenses and other current liabilities	886,124	2,950,077
Operating lease liability		116,314
Total current liabilities	1,513,309	4,220,760
Contingent consideration	1,023,839	1,169,675
Deferred tax liability	390,733	495,113
Accompanying warrants liability	2,457,375	3,701,492
Total liabilities	5,385,256	9,587,040
Commitments and contingencies (Note 17)
Shareholders’ equity:
Common stock, $0.00001 par value, 5,377,329 and 1,978,460 shares issued and outstanding at March 31, 2026 and June 30, 2025, respectively	54	19
AAdditional paid-in capital, net of subscription receivable	218,385,436	200,194,324
Accumulated other comprehensive loss, net of tax	(2,067,368)	(2,845,066)
Accumulated deficit	(186,894,178)	(178,346,703)
Total shareholders’ equity	29,423,944	19,002,574
Total liabilities and shareholders’ equity	$ 34,809,200	$ 28,589,614

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Neuphoria Therapeutics Inc. 10-Q